Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. CAS no. is 668270-12-0 and molecular formula is C25H28N8O2.

Market Analysis and Insights: Global Linagliptin Market
The global Linagliptin market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Linagliptin Scope and Market Size
The global Linagliptin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Linagliptin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Purity≥98%
Purity≥99%

Segment by Application
Linagliptin Tablets
Other

The Linagliptin market is analysed and market size information is provided by regions (countries). Segment by Application, the Linagliptin market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Honor Lab
EstechPharma
Hangzhou Longshine Bio-Tech
Morepen
Suzhou Bichal Biological Technology
Dr. Reddy’s
Shaoxing Hantai Pharmaceutical
Tapi Teva
Wisdom Pharmaceutical
Shanghai Wonder Pharmaceutical
Beijing Mesochem Technology